Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
The Opioid Crisis: the data, the science and the humanity
Michael Kleinrock, Director, Research Development, IQVIA Institute for Human Data Science
Jul 12, 2019
  • Blogs
  • The Opioid Crisis the data the science and the humanity

I had the privilege of  participating in a panel discussion at BIO 2019: Opioids: Changing the paradigm of treating pain and addiction - one year later, which examined how far the issue has evolved since 2018’s BIO sessions.

The discussion was a landmark experience, reminding me of the human impact of data, science and research. Human Data Science isn’t just about numbers and methodology, it’s about improving human health and bringing science to support decisions sometimes colored by bias and stigma.

There are few untouched by the tragedy of opioid abuse.  It has devastated families and the societal cost is evident in the urban, suburban and rural communities in which we live. Unlike other diseases, opioid abuse often carries a societal stigma and a raft of judgments that make it even more difficult to address the problem. Our biases can even spill over into the clinical setting, where people from certain racial and ethnic backgrounds are less likely to be prescribed pain medication and more likely to be suspected of drug-seeking behavior.1,2

All of us who study and deliver health care - and set the policy and standards of care that inform treatment for opioid abuse - are struggling. Our focus at the IQVIA Institute is to help optimize human health by bringing data and fact-based insights forward to better inform decision makers in this critical area.

In our recent study, Medicine Use and Spending in the U.S. - A Review of 2018 and Outlook to 2023, we reviewed, among other topics, the trends and effectiveness of our opioid strategies. Prescription opioid volume continued to decline steeply last year as changes in regulations and clinical guidelines, accompanied by high public awareness, drove a 17% decline in total morphine milligram equivalents (MME) dispensed. The biggest decline came from the most potent and dangerous high-dose prescriptions. Prescription opioid volume has declined 43% since the peak in 2011, with prescriptions for 90 MMEs per day or greater declining by 61% (see exhibit).

But as the U.S. experiments with different state- and local-level policies to address regional concerns, the progress has been uneven. States still differ significantly in their per capita use of opioids and medication-assisted treatments (MATs) for substance abuse disorders. All the New England states have enacted new controls on opioid prescribing and support for opioid dependency in the past three years, but they already had lower-than-average opioids per capita but higher MATs per capita. Other states, including those hardest-hit by the opioid crisis, experience relatively high per capita use of both opioids and MATs (see exhibit).

Of course, we’re not really addressing the opioid crisis if we create another crisis by taking pain treatment away from those who have no other options. Pain medicines, including non-narcotic drugs, declined by 21 million prescriptions, driven significantly by the declines in prescription opioid use with little, if any, offsetting use of other types of pain treatment. To address the unmet need, pharma companies are researching medicines and devices that are effective and less addictive, with pain products representing the fifth-largest segment of the late-stage pipeline (see exhibit).

How do we reduce the suffering of every human experiencing pain, while minimizing the equally painful impact of addiction?  There are no easy answers, but the available data could illuminate a path forward for practitioners, researchers and policymakers.

First, there must be an awareness that judgments and preconceptions have been shown to cloud perceptions and influence decisions, preventing us from most effectively addressing all aspects of pain treatment and the opioid crisis.

Second, in the battle against opioid abuse, it is important to remember that improving the health and well-being of humans applies equally to those with severe and intractable pain. Through the intelligent, individualized application of improved standards of care and the development of alternative pain-management approaches, there is the potential to reduce the public-health crisis while addressing the individual crisis of the person in pain.

And importantly, better decisions can emerge by continually tracking the effectiveness of the standard-of-care and policy experiments in different states and countries.

It is our hope that the work of the IQVIA Institute for Human Data Science can continue to make valuable contributions in these efforts.

 

1 Singhal A, Tien YY, Hsia RY. Racial-Ethnic Disparities in Opioid Prescriptions at Emergency Department Visits for Conditions Commonly Associated with Prescription Drug Abuse. PLoS One. 2016;11(8):e0159224. Published 2016 Aug 8. doi:10.1371/journal.pone.0159224

2 Fischer MA, McKinlay JB, Katz JN, et al. Physician assessments of drug seeking behavior: A mixed methods study. PLoS One. 2017;12(6):e0178690. Published 2017 Jun 23. doi:10.1371/journal.pone.0178690

You may also be interested in

Institute Report
Emerging Biopharma’s Contribution to Innovation
Institute Report
Diabetes Costs and Affordability in the United States
Institute Report
Biosimilars in the United States 2020–2024
Blog
Top Five Insights from the IQVIA Institute 2019 Oncology Trends Report
Blog
Quantifying the Impact of R&D Trends on Trial Productivity
Video
The IQVIA Institute for Human Data Science
Prev
Next
Contact Us